NCT00678327View on ClinicalTrials.gov

Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

PHASE3CompletedINTERVENTIONAL
Enrollment

1,202

Participants

Timeline

Start Date

August 29, 2008

Primary Completion Date

January 31, 2016

Study Completion Date

May 1, 2024

Conditions
Lymphoma
Interventions
BIOLOGICAL

bleomycin sulfate

Given IV

BIOLOGICAL

filgrastim

Given subcutaneously

BIOLOGICAL

pegfilgrastim

Given subcutaneously

DRUG

cyclophosphamide

Given IV

DRUG

dacarbazine

Given IV

DRUG

doxorubicin hydrochloride

Given IV

DRUG

etoposide

Given IV

DRUG

prednisolone

Given orally

DRUG

procarbazine hydrochloride

Given orally

DRUG

vinblastine sulfate

Given IV

DRUG

vincristine sulfate

Given IV

Trial Locations (1)

SO16 6YD

Southampton General Hospital, Southampton

Sponsors

Collaborators (1)

Cancer Research UK
All Listed Sponsors
collaborator

Cancer Research UK

OTHER

collaborator

Cancer Research UK & UCL Cancer Trials Centre

OTHER

lead

University College, London

OTHER

NCT00678327 - Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter